Hans Bentzen

Nordic <scp>MCL</scp>2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by <scp>BEAM</scp> or <scp>BEAC</scp> + autologous stem‐cell support: still very long survival but late relapses do occur

Christian H. Geisler, Arne Kolstad, Anna Laurell et al. · British Journal of Haematology · 2012 · 265 citations

Cell Therapy, Immunology, Pathology +22

15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (<scp>MCL</scp>2): prolonged remissions without survival plateau

Christian Winther Eskelund, Arne Kolstad, Mats Jerkeman et al. · British Journal of Haematology · 2016 · 207 citations · Full text

Immunology, Pathology, Hematological Malignancy +16

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Arne Kolstad, Anna Laurell, Mats Jerkeman et al. · Blood · 2014 · 103 citations · Full text

Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans

Robert S. Pedersen, Hans Bentzen, Jesper Nørgaard Bech et al. · American Journal of Physiology-Renal Physiology · 2001 · 89 citations

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Arne Kolstad, Lone Bredo Pedersen, Christian Winther Eskelund et al. · Biology of Blood and Marrow Transplantation · 2016 · 62 citations · Full text